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Background: To present empirical data on how the variation in regulating clinical research and patient care was
perceived in Finland between 2009 and 2012.
Methods: Notes of interviews with 22 research ethics committee (REC) chairpersons were analyzed to identify
whether differences in the regulation of clinical research and patient care were addressed. REC chairpersons’
opinions on three imaginary cases of clinical research projects challenging current research ethics rules (vignettes)
were requested with a questionnaire; 18 of the 22 interviewed chairpersons responded.
Results: Based on REC chairpersons’ interviews, the differences between care and research regulation were not
considered important issues in Finland. In the vignettes, REC chairpersons’ assumptions on how their REC would
decide varied in regard to allowing research without informed consent, while solutions that are not allowed by current
law were even anticipated. Mostly, but not always, the chairpersons’ own personal view agreed with their REC.
Conclusions: The distinction between care and research regulation has not been publicly challenged by Finnish RECs,
even though it is a challenge when research relevant to health care is carried out. There is a need for debate and
changes in laws and practices.
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It is often argued that medical care aims to provide optimal
care for an individual patient while research aims to
produce generalizable knowledge for the benefit of
future patients. However, this distinction is unclear in
complex health care systems aiming for evidence-based
care [1]. Faden et al. [2] have argued that classification
schemes that bifurcate learning activities into two crude
categories of research and practice are increasingly out-
moded. The origin for this distinction has been traced to
the influential 1979 Belmont report in the USA [3]. Before
that, research and care were often intertwined [1].
Current problems in clinical research include the issue
that some important questions have been neglected [4]
and the applicability of research to real care situations* Correspondence: elina.hemminki@thl.fi
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article, unless otherwise stated.is not clear [5]. To increase knowledge creation, it has
been suggested that health care and research should be
better integrated and the current norms distinguishing
these two should be modified [4,6,7]. It has been suggested
that research is a responsibility and a priority for both
patients and health professionals [8-20], and that the
integration of research within everyday clinical practice
would help achieve a more efficient arrangement for
research [11-16].
The purpose of this paper is to present empirical data
on how the variation in regulating clinical research and
patient care is perceived in Finland. We studied i) whether
the distinction has been an issue in Finland (using expert
interviews) and ii) how ethics committees are likely to de-
cide about clinically relevant research projects challenging
current research ethics rules, using three fictitious cases
(vignettes).tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Finland is one of the Nordic welfare states. Its population
of about 5.4 million is homogenous and well-educated.
Health service funding has two co-existing systems: a
community based, tax-funded area-based system cover-
ing most in-patient care and most out-patient care, and
private care in part subsidized by national health insurance.
Some other sickness costs are also partly reimbursed.
Finland has a strong tradition for clinical research [21].
All clinical research has to be reviewed by official local
research ethics committees (RECs) or the central commit-
tee. The law defines two functions of the central committee:
to handle multinational drug trials (since 2010 all drug
trials) and to support local RECs in ethics principles and
in organizing education. The support functions have been
relatively modest and the composition of the committee
is tailored for the review of drug trials. The committee
can delegate the handling of drug trials to local RECs,
and most have been delegated (Hemminki E, unpublished
data 2014).
There is one binding international research ethics
instrument, the Convention on Human Rights and
Biomedicine (Oviedo Convention). Other international
codes valid in Finland include the Declaration of
Helsinki, the Universal Declaration on Bioethics and
Human Rights, the International Ethical Guidelines
for Biomedical Research Involving Human Subjects,
the Good Clinical Practice Guidelines, and the additional
protocol of the Oviedo Convention concerning Biomedical
Research [22]. The codes start from a principle that
research is an activity to be clearly separated from care
and that these two have their own rules with different
reasoning and responsibilities. The codes do not provide
guidance on how the problems resulting from this division
could be solved, nor do they state the course of action in
cases where research blends with care or the situations in
which informed consent can be exempted.
Different laws apply to care and research in Finland.
The key law regulating medical research is the Medical
Research Act, first passed in 1999 with amendments in
2004 and 2010. In 2004, the Clinical Trials Directive
covering clinical trials on medicinal products in the EU
was integrated into the Medical Research Act (as well as
into drug legislation), defining drug trials as a subgroup
of medical research with some special requirements.
However, some principles from the EU directive were
enlarged to cover medical research as a whole [23]. In all
drug research, even in emergency situations, an informed
consent is needed, either from patients themselves or their
relatives or guardians; no waivers are allowed.
The main changes in 2010 were to enlarge the scope of
the law from a narrow medical (physician led) perspective
to a health research (including nursing research, studies
with registers, and with human blood and tissue samples)perspective; to reduce the number of ethics committees
from 21 to 5 (plus a central committee); to strengthen the
role of the central committee; to allow children to have
more rights to decide on research participation; and to
administratively transfer the central committee to another
institute (from the general medical ethics committee,
which dealt with health and social care ethics, to a
medico-legal body). The background document to change
the Medical Research Act in 2009 was detailed, but
there was no discussion of the relation between research
and care.
The 2011 Health Care Act (Terveydenhuoltolaki) in-
cludes various statements on research and a statement on
the need for health care to be based on evidence. However,
no advice on how evidence-based health care is to be
achieved is given and the law does not take a stand on
differences in regulating care and research. The long
background document to the law contains little on research
and nothing on the integration of research and care.
Methods
This current study is a part of a larger study, with data
collected by various methods [21]. To answer our question
on whether distinction between clinical research and
patient care had been an issue, chair-persons of RECs
were interviewed. To find out how ethics committees
are likely to decide about clinically relevant research
projects challenging current research ethics rules, we
used three fictitious research projects (vignettes).
All chairpersons of the Finnish official medical RECs
in continental Finland were contacted. Of the 25 chair-
persons, 22 (18 men and 4 women) were interviewed in
Finnish by one of two researchers, a dentist and a law-
yer, in 2010–11. The chairpersons were approached as
experts, meaning knowledgeable persons who were
asked to describe their experience and views, rather
than research subjects. That approach influenced how
they were contacted and interviewed, as well as the style
of vignettes. For the same reason, we decided not to use
voice-recording. We thought that some experts may
consider the topic sensitive and that “discussion style”
would work better.
Interviews with REC chairpersons were semi-structured.
An interview guide was made, but each interview was
tailored for the interviewees’ position, expertise, and
interests. The interviews lasted from 30 minutes to
2 hours. During the interviews, notes were made and a
summary of the answers and discussion was written
down after the interview. We did not have a specific
question on the relation between care and research, but
a number of related questions, such as: What is the
main focus in regulating research? Is it clear which
regulation should be used for which type of research?
Which factors promote or hinder research? What are
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What should be changed in research regulation?
All interview notes were read by one researcher (EH)
and analyzed for the following themes: i) need for (clinical)
research of health care, ii) optimality of current rules, iii)
comparison of rules for care and research, and iv) any
other aspect on the relation between care and research. If
any of the four themes had been discussed, the relevant
sections were transferred to a separate document. As the
comments on research and care were few (see Results),
there was no need to develop refined coding.
After the interview, the REC chairpersons were given a
questionnaire presenting three fictitious cases (Additional
file 1). The cases were designed to challenge current
research ethics rules (all were planned to be made
without informed consent), but were clinically relevant.
They were modified and combined from actual research
protocols. Chairpersons were first asked to select a re-
sponse which most closely matched their opinions of how
the study would be reviewed by their ethics committee.
Secondly, chairpersons were asked whether they thought
the review decisions would correspond with their own
personal ethics. Additional open comments were asked
with an ample empty space.
Most REC chairpersons completed the questionnaire
during the interview, but due to time constraints some
took it with them and sent their responses later via mail
or e-mail. Of the 22 interviewed chairpersons, 18 (81%)
returned responses; based on all 25 chairpersons initially
approached, the response rate was 72%. Of the 25
approached, two declined to return the form and 5 did
not send the form despite having originally indicated
that they would. The answers in the fixed questions were
tallied. Correspondence to chairpersons’ own ethical views
were calculated by each answer alternative (Tables 1, 2, 3).
Comments were counted and their content classified by
the topic and the content (see Results).
The whole project (MERGO Ethical review and ad-
ministrative governance of clinical research) received aTable 1 Research ethics committee (REC) replies to a fictitiou
informed consent (IC), case 1 in Additional file 1): how they a
with the decision, numbers1 (n of respondents = 18)
REC
decision
Accept no informed consent (IC) 4
IC for intervention from collective 3
IC for data collection from collective 2
IC from patients to collect clinical data 7
IC from patients to answer questionnaire 6
Other 0
1In REC decision REC chairperson could choose more than one option.
2Agreed: chairperson agreed fully; Somewhat: chairperson agreed somewhat; No: dpositive statement from the ethics committee of the Na-
tional Institute for Health and Welfare (June 17, 2010,
amendment Jan 27, 2011). All interviews were voluntary
and interviewees knew the purpose.
Results
Interviews
We interviewed 22 ethics committee chairpersons. Vari-
ation in the rules between care and research was not expli-
citly brought up. However, some chairpersons in smaller
hospitals said that research and clinical care are integrated
and that this is as it should be. Some interviewees believed
that the proposal to transfer the ethics handling of all
medical research to the five university RECs decreased
attractiveness of research in smaller hospitals. It was
considered a problem, as research was considered useful
to the hospital.
The researcher as the care-giving doctor was mentioned
a few times, but it was mentioned as an ethical problem
rather as a positive thing for integrating research and care.
The concern was that voluntary participation may be
endangered. In one interview, another view was given:
researchers should not directly recruit patients, but it
should occur via care-giving doctors.
Ethics committee (REC) chairpersons’ views on three
imaginary research projects
The first case was a cluster-randomized health service
trial that mixed care and research and which did not
seek informed consent from patients: 30 health centers
were to be randomized in terms of receiving or not
receiving a computer-aided decision-making tool for
doctors; patients were to be asked their experiences
afterwards by mailed anonymous questionnaires and
patient outcomes were to be collected from patient records
(Additional file 1).
The assumption of chairpersons on how their REC
would decide about the project varied (Table 1). Four
out of 18 chairpersons thought that their REC woulds research protocol (Cluster randomized trial without
ssumed their REC would decide and whether they agreed
Own ethical view
Agreed2 Somewhat2 No2
4 0 0
2 1 0
1 1 0
5 2 0
1 5 0
– – –
id not agree.
Table 2 Research ethics committee (REC) replies to a fictitious research protocol (A study mixing care and research in
intervention, case 2 in Additional file 1): how they assumed their REC would decide and whether they agreed with the
decision, numbers1 (n of respondents = 18)
REC
decision
Own ethical view
Agreed2 Somewhat2 No2
Accept no informed consent (IC) 8 5 3 0
IC for intervention from collective 3 3 0 0
IC for data collection from collective 1 0 0 1
IC from patients for intervention and data collection 8 5 3 0
Other 1 1 0 0
1In REC decisions REC chairperson could choose more than one option.
2Agreed: chairperson agreed fully; Somewhat: chairperson agreed somewhat; No: did not agree.
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from anyone. Three suggested that the informed consent
could be asked from a collective, such as a municipality
health board. Seven suggested that patients should be
asked about collecting data from their routine clinical
records and six would have required informed consent
to be given even for the anonymous questionnaire.
Chairpersons’ own personal ethical view agreed with the
assumed decision of their REC either fully or somewhat
(Table 1). The requirement for informed consent in an-
onymous questionnaires was assumed to be a requirement
of the REC more often (n = 6) than it was considered a re-
quirement by the chairpersons themselves (only one fully
agreed with this view). Four chairpersons had commented
further on the fixed responses.
The second imaginary research project (vignette 2,
Additional file 1) was an individually randomized health
service trial that mixed care and research without
informed consent from patients. Patients were to be
randomized to a nurse or doctor as the first contact in
an emergency room; both were existing practices in
the study health centers but used unsystematically.
The outcomes were health professionals’ opinions (col-
lected by questionnaires) and patients’ health status (data
collected from patient records). The researchers referred
to the project as development work.Table 3 Research ethics committee (REC) replies to a fictitiou
having sales license for another indication, case 3 in Addition
whether they agreed with the decision, numbers1 (n of respo
REC
decision
Accept no informed consent (IC) 0
IC for intervention from collective 4
IC for data collection from collective 3
IC afterwards 7
Other3 6
1In REC decision REC chairperson could choose more than one option.
2Agreed: chairperson agreed fully; Somewhat: chairperson agreed somewhat; No: d
3Other: includes rejections (3 chairpersons).The assumptions of chairpersons on how they thought
their REC would decide varied (Table 2). Eight out of 18
chairpersons anticipated that their REC would accept
the design and eight anticipated that the REC would
request informed consent from patients both for the
intervention and the data collection, as well as to exclude
patients who declined. Three anticipated informed con-
sent from a collective for the intervention and one for the
data collection (REC chairperson could choose more than
one option).
The personal views of chairpersons on what was ethic-
ally correct were mostly in accord with what they assumed
their REC would decide, but not fully (Table 2). In one
case, the chairperson disagreed with the anticipated deci-
sion of their REC (informed consent for data collection
from a collective); he thought that no informed consent
was needed.
Five chairpersons had given additional comments. One
wrote that, as the assignment to nurses and the assign-
ment to doctors have both already been used, there is no
ethical problem in randomizing this assignment. Four
others defended their requirement for informed consent
from patients. Three justifications were normative: inter-
ventions always require permission from the patient.
Two said that randomization makes the difference. One
chairperson provided an ethical argument: in a normals research protocol (An emergency trial with a drug
al file 1): how they assumed their REC would decide and
ndents = 18)
Own ethical view
Agreed2 Somewhat2 No2
– – –
0 4 0
1 2 0
3 4 0
1 1 4
id not agree.
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algorithm, while randomization would influence the care
of an individual patient.
The third imaginary research project (vignette 3,
Additional file 1) was an emergency trial with a licensed
drug given by ambulance personnel without informed
consent. No chairperson anticipated the study design
being accepted (Table 3). Seven anticipated a require-
ment that informed consent be obtained afterwards. Some
chairpersons (four chair-persons for the intervention
and three for data collection) anticipated that their
REC would suggest informed consent from a collective.
Three chairpersons anticipated that their REC would
give a negative statement for the study (reject).
In the case of vignette 3, REC chairpersons less often
considered their own ethical valuations to be in agreement
with the anticipated decisions of their REC than with
the previous vignettes. Even explicit criticism of their
REC decision was given. Of the three chairpersons who
assumed that the project would be rejected, only one
fully agreed with the REC decision and two thought
that the decision was not ethically reasonable.
Vignette 3 also raised many additional comments and
eight were on substance. Three chairpersons commented
that all specified options in the vignette were against the
current law, and two wrote that the current law was not
good. One put it: “The ethics committee should obey the
law… Thus new evidence-based treatment will not be
available”. One wrote clearly that (the law) is wrong and
should be changed. One suggested obtaining permission
from a relevant authority (not a specified option), and
three suggested asking for permission afterwards. One
chairperson wrote that his REC would ask for permission
afterwards either from the patient or a relative, but not in
the case of dead patients. The comment implicitly made
clear that the chairperson knew their practice (apparently
also used in real situations) could be challenged on legal
grounds, but he thought it was ethically correct.
Discussion
The purpose of this paper was to present empirical data
on how the variation in regulating clinical research and
patient care has been perceived by Finnish experts,
chairpersons of RECs. Our main finding was that this
variation apparently had not been widely discussed in
Finnish RECs, but the imaginary cases (vignettes) sug-
gested the existence of a problem. In some other countries,
variations in the ethics and regulations governing care
and research have been well debated, but we found no
empirical studies with which to compare our own results.
Based on the interviews with the chairpersons of the
RECs, the distinction between regulations governing care
and research has not been an important issue in Finnish
practice or debates. The REC-chairpersons’ assumptionson how their REC were likely to decide suggested a large
variation in the decision-making for research projects
involving cluster randomized trials and those challenging
current ethics rules. Quite likely, the presented studies
would be allowed by some RECs but not by others. Thus,
the decision would depend on the committee that the
researcher had sent his application to. The personal ethics
of most of the chairpersons agreed with the assumed deci-
sion of their REC, but not always. This, and the varying
REC decisions, may suggest unfamiliarity with the issue,
but also an active questioning of the current ethics rules.
The study includes a number of limitations. First, the
decision on the imaginary study plans (vignettes) was
based on the chairperson’s guess of his/her REC behavior.
It is difficult to know how the decision would be in reality
when a detailed study plan would be presented to a com-
mittee. The validity of the vignettes was not formally
tested. However, the researchers within the group read
and modified the vignettes to make them clear, and
feed-back from the first chairperson interviews showed
that vignettes were clear to the respondents.
Secondly, the interviewees were not voice-recorded
and the quality of notes is likely to vary, e.g., how quickly
and concisely the interviewee spoke and how much med-
ical jargon he/she used. Voice-recording was considered,
but rejected. We thought that “discussion style” would
work better. We wanted to get their views and not the “of-
ficial” ones stipulated by their position.
Chairpersons were not asked specifically about the
issues of having different regulation for treatment and
practice. However, the findings of chairperson interviews
that the issue of distinction between regulations governing
care and research has not been an important issue in
Finland is consistent with other data. Our unpublished
data from documents and interviews with other experts in
research and health services other than research ethics
committee chairpersons showed the same: the principle
of having different rules for research and clinical care
had not been challenged in public debate or publicly
available documents, even though many considered clinical
research important for health care. As the requirement for
informed consent for all types of medical research is well
known among the medical research community, proposals
have been tailored from the beginning to suit the detailed
requirements for informed consent.
However, our incidental observations from individual
projects mixing care and research show that it has been
an issue for individual researchers. We have observed
that researchers have used definitional solutions to make
research mixing care and research possible. Research pro-
jects have been defined as programs or care experiments
to avoid unsuitable requirements entailed in research
regulation. Projects have likewise been defined as non-
medical research; such projects in Finland do not have
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some researchers are familiar with the problems relating
to mixing care and research, but rather than raising the
issue have chosen to search for ad hoc solutions. Possibly,
these researchers have felt that changing the ethics codes
and research law may be too challenging. It is also possible
that the problems of permissions, quality assurance, and
development work are known to some ethics committees
and institutes overseeing health care in Finland, but
related discussions do not occur in public.
The Finnish medical research law was recently (2010)
changed, and that would have offered an opportunity to
solve some of the problems, but the opportunity was
not used. An explanation could be that there were other
issues in research regulation and financing which domi-
nated the interest of law makers and medical experts. A
law on biobanks was drafted and in that context the use of
existing data was debated. The 2010 research legislation
proposed disbanding most official ethics committees and
at the same time university hospitals were given increasing
power to decide about the use of research money from
the state. Smaller hospitals might have feared that they
would lose research money. That could explain the research
ethics committee chairpersons of smaller hospitals saying
that research and clinical care are integrated and that this
is as it should be.
The first vignette was a cluster randomized trial without
informed consent. The requirements for informed consent
in cluster randomized trials vary between countries, within
a country, and by the type of trial [24]. The Finnish
research legislation assumes an informed consent from
the participants and does not advise on how to handle
this kind of research. In this study, the concept of ‘a
participant’ is not clear, as it was health care centers
and not patients, that were randomized. Furthermore,
patients are not expected to decide how physicians
make their diagnosis. Many REC chairpersons chose the
alternative of obtaining the information from a collective,
which has been previously proposed for these types of
studies [25], but is not recognized in the Finnish re-
search law. If this would have been a real situation and
a REC would not have accepted the proposed application,
researchers might have defined the project as a develop-
ment project, or the researchers would have modified
the design to meet the REC requirements. In the last
option, we argue that asking for patient consent would
have weakened the study design and feasibility.
The main difference between the second and first
vignettes was that patients, as opposed to health care
units, were randomized. Often, the mere act of random-
ization is considered to define an activity to be research
requiring patients’ consent, but this has also been chal-
lenged [2,24]. If the patients would have been asked for an
informed consent to be randomized to a doctor or nurse,the study results would not have been useful in the organ-
izing of an emergency care unit, as it would likely merely
reflect patient preferences only.
The third vignette was an emergency trial with a drug
already registered for another indication. This case expli-
citly made visible the fact that the legislation does not
always agree with good ethics. The case was built in such
a way that it was not possible to obtain informed consent
from patients or their relatives, as would be required by
the current law. All the formulated choices for the REC
decisions were against the Finnish law, even though not
against international codes or interpretations elsewhere
of the EU clinical trials directive. The REC chairpersons’
answers to this case showed, besides a lack of knowledge
of the current law by some chairpersons, a moral conflict
between obeying the law and carrying out ethical deci-
sions. In reality, researchers might have modified the
plan to be a care experiment and used the drug as
planned, but without concurrent controls. Doctors are
free to use drugs for unlicensed purposes provided it is
medically defendable. In some other European countries,
informed consent can be waived in emergency drug trials
[26,27], but not in Finland.
New research approaches are being increasingly used.
They include epidemiological research using biobanks
and registers, as well as trials testing care structures
and care delivery (including randomized care). However,
current research regulations and codes hinder these
approaches [17]. Making a clear distinction between
continuous improvement activities (including clinical
effectiveness assessment and quality improvement) and
public health programs is difficult. The current ethics rules
are unsatisfactory for these approaches [2,4,6,25,28-31].
For example, the individual informed consent and right to
withdraw from the study at all stages are poorly applicable
in many of these studies. The concept of “learning health
care”, which covers research and various other activities to
obtain information to improve health care, has challenged
the ethics rules [2].
This problem is most evident in research designs that
cannot easily apply current requirements for informed
consent and the right to withdraw [4,6]. Informed consent
is the key practical tool to separate care and research [26].
In Finland, written informed consent is a mandatory re-
quirement in medical research, but it is not sought in
medical care, not even in cases involving extensive sur-
gical operations. In medical care, an implicit permission
is assumed.
The different standards applied to research and care have
been discussed at least since the 1960s [1,2,11,18-20,32-34],
but little has happened in terms of developing regula-
tions. In recent years, discussion and activities have
begun to emerge among policy makers in some countries
[4,28,30,11,35]. In the UK, practices around medical
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research within and by health care [30,36]. A special regis-
try that records a sub-class of randomized care – random-
ized health services studies – has been established as
analogous to the registers of clinical trials [29].
Based on our study and on previous studies and obser-
vations, we recommend that, in Finland, the current laws
and rules, or their interpretation, regulating research and
its definitions should be revisited and modified to allow
better integration of clinical research and ordinary health
care. Particularly, informed consent should not be the sole
method to avoid coercion and manipulation in research
focusing in care delivery and community actions, and
alternatives to individual informed consent should be
searched for. Waivers for informed consent are needed.
It is likely that these recommendations apply to many
other European countries as well.
Additional file
Additional file 1: The questionnaire on fictitious cases (vignettes)
presented to ethics committee chairpersons.
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